Targeting EZH2 as a therapeutic strategy for primary PCa or CRPC is considered particularly interesting as EZH2 not only serves as coactivator of AR, but also binds to the AR promoter region to amplify its expression [83]. Here, AR is linked to posterior cortical atrophy.